Aktie 300391 CHANGJIANG PHARMACEUTICAL GROUP CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Changjiang Pharmaceutical Group Co., Ltd.

Aktien

300391

CNE100001XN8

300391

Schlusskurs Shenzhen S.E.
Andere Börsenplätze
 00:00:00 04.07.2024 		% 5 Tage % 1. Jan.
3,85 CNY +14,24 % Intraday Chart für Changjiang Pharmaceutical Group Co., Ltd. +59,75 % -50,26 %
04.07. Changjiang Pharmaceutical ernennt Vorsitzenden; Aktien steigen um 3% MT
02.07. Changjiang Pharmaceutical Group Co., Ltd. Genehmigt Änderungen im Vorstand CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Changjiang Pharmaceutical Appoints Chair; Shares Up 3%
Changjiang Pharmaceutical Group Co., Ltd. Approves Board Changes
Yichang HEC Still Negotiating Merger Deal with Sunshine Lake Pharma
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Yichang Hec Changjiang Pharmaceutical Updates on Possible Merger with Sunshine Lake Pharma
Yichang Hec Changjiang Pharmaceutical's Net Profit Surges in 2023 as Revenue Jumps
YiChang HEC ChangJiang Pharmaceutical's Profit Surges in 2023
Yichang Hec Changjiang Pharmaceutical Expects Up to 2,627% Profit Surge in 2023
HEC ChangJiang Pharmaceutical Increases Transaction Limits Under 2 Contracts
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
HEC ChangJiang Pharmaceutical's Insulin Injection Cleared for Market Launch in China
HEC ChangJiang Pharmaceutical Returns to Profit on Surge in Anti-Viral Drug Sales
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
China Greenlights New Drug Application for HEC ChangJiang Pharmaceutical's Hepatitis C Drug
HEC ChangJiang Pharmaceutical Forecasts Surge in H1 Profit; Shares Rise 5%
Yucong Tianshun No. 2 Private Equity Securities Investment Fund managed by Shanghai Yucong Asset Management Co., Ltd completed the acquisition of 5.9942% stake in Changjiang Pharmaceutical Group Co., Ltd. from Changxing Shengshi Fenghua Business Co., Ltd.
HEC ChangJiang Pharma Repurchases $400 Million Convertible Bonds Issued to Blackstone
Yucong Tianshun No. 2 Private Equity Securities Investment Fund managed by Shanghai Yucong Asset Management Co., Ltd signed Share Transfer Agreement to acquire 5.9942% stake in Changjiang Pharmaceutical Group Co., Ltd. from Changxing Shengshi Fenghua Business Co., Ltd. for CNY 154.14 million.
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 300391 Aktie
  4. Nachrichten Changjiang Pharmaceutical Group Co., Ltd.
  5. Andere Sprachen